Kenya's pharmacy board issues alert on counterfeit cancer drug Herceptin
The PPB strongly advised against the use, distribution, sale, or supply of the C5830083 batch due to its inability to guarantee its safety, quality, and efficacy.
The Pharmacy and Poisons Board (PPB) has issued an alert regarding a batch of counterfeit Herceptin 440mg (Trastuzumab 440mg) that it says has been circulating in Kenya.
According to the product website, "Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal Growth Factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes".
More To Read
- Pharmacy and Poisons Board recalls substandard batches of Paracetamol, Augmentin
- Pharmacy and Poisons Board lifts ban on popular painkiller Mefnac Oral Suspension
- Pharmacy Board raises alarm over mishandling of medical products
- State fights fake drugs with advanced on-site screening tools
- Public warned over unregistered and substandard cancer drug in the market
- Pharmacy Board orders withholding of drug used to relieve menstrual pain over contamination concerns
This batch, number C5830083 and purportedly manufactured by Roche Products Ltd. in Germany, has December 2021 and November 2024 as the manufacture and expiration dates, respectively.
"The public is notified that this specific product, batch number C5830083 is confirmed to be counterfeit," the PPB's chief executive, Fred Sioyi, said in a statement on Saturday.
"It is not authorised to be in the market and is a falsified product in view of the falsified contents, packaging, and labelling aspects, which have been confirmed by the brand owners."
The PPB strongly advised against the use, distribution, sale, or supply of the batch due to its inability to guarantee its safety, quality, and efficacy.
The agency said that, in collaboration with relevant government agencies, it has taken legal and regulatory measures against individuals suspected of involvement in the illicit activity, as per the provisions of the Pharmacy and Poisons Act (Cap. 244).
Additionally, the PPB said it has intensified market surveillance to safeguard public health and ensure product safety.
"We urge members of the public and healthcare providers to report and volunteer information on suspicious activities that may be related to such acts of falsification as well as all suspicious, substandard, and falsified medical products."
Top Stories Today
- Supreme Court Judge Ouko warns of eroding public trust due to case delays
- KNEC announces July, August deadlines for 2025 CBC assessments
- Kenya aims to quadruple tea exports to China by 2030
- Palestine lifts ban on Al Jazeera's operations in Palestinian territories
- State allocates Sh4.8 billion for SGR local control, Malaba extension
- UDA dismisses Gachagua’s resignation from party as 'theatrics'
- Reprieve for electorates as IEBC reconstitution sets stage for by-elections
- Google quietly refreshes iconic 'G' logo with subtle design tweaks
- Nairobi court denies bail for Lebanese suspect facing US extradition
- Fire burns shops at Mogadishu's Bakaara market, no casualties reported
- Tanzania electoral agency unveils 8 new constituencies, 5 wards ahead of polls
- UN urges ceasefire in North Darfur amid growing humanitarian crisis
- Farming hero feeding Kiambiu slum against all odds
- DCI summons Mukuru activists over suspected links to BBC documentary
- Finland's President makes historic visit to Kenya as Nordic-Africa ties deepen
- AUSSOM on the brink: Funding crisis threatens AU's Somalia mission
- Treasury proposes budget cuts for Moi, Egerton and TUK amid wage woes
- Betting firms may be rigging outcomes to avoid taxes, MPs warn
- Kenyans given until May 21 to submit views on IEBC nominees
- Algeria orders expulsion of French embassy staff over "protocol breaches"
